Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 60,547 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 60,547 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $0.40, for a total transaction of $24,218.80. Following the transaction, the director directly owned 377,211 shares in the company, valued at approximately $150,884.40. The trade was a 13.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Friday, June 5th, Luke Evnin sold 24,946 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total transaction of $9,978.40.
• On Thursday, June 4th, Luke Evnin sold 20,072 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.44, for a total transaction of $8,831.68.
• On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total transaction of $12,494.58.
• On Tuesday, June 2nd, Luke Evnin sold 29,595 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $13,317.75.
• On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total transaction of $37,815.73.
• On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $14,650.20.
• On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.46, for a total transaction of $12,741.08.
• On Wednesday, May 27th, Luke Evnin sold 80,852 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.48, for a total value of $38,808.96.
• On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total value of $31,936.50.
• On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $39,341.25.

Werewolf Therapeutics Stock Down 2.7%

Shares of HOWL stock opened at $0.38 on Tuesday. Werewolf Therapeutics, Inc. has a 12 month low of $0.37 and a 12 month high of $2.38. The business’s 50 day moving average is $0.70 and its two-hundred day moving average is $0.73. The company has a market cap of $18.56 million, a PE ratio of -0.31 and a beta of 0.29.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, equities analysts expect that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HOWL has been the topic of several analyst reports. Wall Street Zen downgraded Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Werewolf Therapeutics currently has an average rating of “Hold” and an average price target of $3.75.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Susquehanna International Group LLP lifted its position in Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after purchasing an additional 13,439 shares during the period. Vontobel Holding Ltd. lifted its position in Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares during the period. Regal Investment Advisors LLC lifted its position in Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares during the period. Bank of America Corp DE lifted its position in Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares during the period. Finally, Qube Research & Technologies Ltd bought a new position in Werewolf Therapeutics in the second quarter worth $48,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.